YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP

Gaithersburg, Maryland, November 15, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company...

YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine

Gaithersburg, Maryland, November 10, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company...

YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.

• Transaction values YS Biopharma at pre-money equity value of $834 million • Certain investors (“Forward Purchase Investors”) are expected...

YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine

Beijing, China - September 8, 2022 - YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and...

YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization

Beijing, China – February 24, 2021 – YishengBio Co., Ltd. ("YishengBio", the "Company") announced today the closing of a US$130...